Published in Schizophr Bull on July 11, 2011
Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet (2013) 1.57
Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 1.42
In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull (2012) 1.28
Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology (2012) 1.19
Deleterious GRM1 mutations in schizophrenia. PLoS One (2012) 1.16
Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol (2015) 1.14
The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study. Neuropsychopharmacology (2012) 1.03
Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology (2012) 1.02
Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry (2013) 1.00
Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change. J Neurosci (2015) 1.00
Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol (2015) 0.97
Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry (2014) 0.97
Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain? Schizophr Bull (2016) 0.97
Resting-state glutamate and GABA concentrations predict task-induced deactivation in the default mode network. J Neurosci (2013) 0.96
Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology (2013) 0.95
GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study. Neuroimage Clin (2014) 0.95
Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr Bull (2013) 0.94
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr (2012) 0.91
Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin Neurosci (2013) 0.90
Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol Psychiatry (2014) 0.90
Translating the MAM model of psychosis to humans. Trends Neurosci (2014) 0.89
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr Res (2015) 0.88
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia. Neurosci Biobehav Rev (2015) 0.88
Ketamine Dysregulates the Amplitude and Connectivity of High-Frequency Oscillations in Cortical-Subcortical Networks in Humans: Evidence From Resting-State Magnetoencephalography-Recordings. Schizophr Bull (2015) 0.88
Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology (Berl) (2013) 0.87
Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol (2012) 0.86
Nicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait. Front Pharmacol (2012) 0.86
Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia. Schizophr Res (2014) 0.86
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophr Bull (2015) 0.85
Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry (2014) 0.85
Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks. Neuropsychopharmacology (2014) 0.84
Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol (2014) 0.84
Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. Schizophr Bull (2014) 0.83
Increased Cerebellar Functional Connectivity With the Default-Mode Network in Unaffected Siblings of Schizophrenia Patients at Rest. Schizophr Bull (2015) 0.83
Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study. Mol Psychiatry (2015) 0.83
Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res (2013) 0.83
Drug models of schizophrenia. Ther Adv Psychopharmacol (2015) 0.82
Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry (2015) 0.82
Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. Curr Opin Psychiatry (2016) 0.82
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology (2014) 0.81
Deciphering the role of docosahexaenoic acid in brain maturation and pathology with magnetic resonance imaging. Prostaglandins Leukot Essent Fatty Acids (2012) 0.81
Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study. Neuroscience (2014) 0.81
Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull (2014) 0.81
Bridging Levels of Understanding in Schizophrenia Through Computational Modeling. Clin Psychol Sci (2015) 0.81
Synapsin II gene expression in the dorsolateral prefrontal cortex of brain specimens from patients with schizophrenia and bipolar disorder: effect of lifetime intake of antipsychotic drugs. Pharmacogenomics J (2013) 0.81
What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. Mol Psychiatry (2014) 0.81
The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Adv Pharmacol (2016) 0.79
Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. Neuroimage Clin (2014) 0.79
Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol (2015) 0.79
Patients with first-episode, drug-naive schizophrenia and subjects at ultra-high risk of psychosis shared increased cerebellar-default mode network connectivity at rest. Sci Rep (2016) 0.79
Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study. Schizophr Res (2014) 0.79
Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol Res Perspect (2015) 0.79
Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. NPJ Schizophr (2015) 0.78
Functional hierarchy underlies preferential connectivity disturbances in schizophrenia. Proc Natl Acad Sci U S A (2015) 0.78
Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis (2012) 0.78
Frontal P3 event-related potential is related to brain glutamine/glutamate ratio measured in vivo. Neuroimage (2015) 0.78
Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. Curr Neuropharmacol (2015) 0.78
Increased Causal Connectivity Related to Anatomical Alterations as Potential Endophenotypes for Schizophrenia. Medicine (Baltimore) (2015) 0.78
Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A (1)H-MRS and pCASL study. Neuropsychopharmacology (2016) 0.77
Auditory hallucinations: A review of the ERC "VOICE" project. World J Psychiatry (2015) 0.77
Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T. NMR Biomed (2015) 0.77
Schizophrenia: a systemic disorder. Clin Schizophr Relat Psychoses (2014) 0.77
A Comprehensive Review of the (1)H-MRS Metabolite Spectrum in Autism Spectrum Disorder. Front Mol Neurosci (2016) 0.77
Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. Schizophr Bull (2015) 0.77
Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia. Curr Mol Med (2015) 0.77
Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. PLoS Med (2016) 0.77
Detection of Glutamate Alterations in the Human Brain Using (1)H-MRS: Comparison of STEAM and sLASER at 7 T. Front Psychiatry (2017) 0.77
Sleep and plasticity in schizophrenia. Curr Top Behav Neurosci (2015) 0.76
Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia. Psychol Med (2014) 0.76
Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. Int J Neuropsychopharmacol (2014) 0.76
Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Front Hum Neurosci (2015) 0.76
In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T. Schizophr Bull (2013) 0.76
Brain in flames - animal models of psychosis: utility and limitations. Neuropsychiatr Dis Treat (2015) 0.76
Anterior insula GABA levels correlate with emotional aspects of empathy: a proton magnetic resonance spectroscopy study. PLoS One (2014) 0.76
Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms. Dialogues Clin Neurosci (2015) 0.76
Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T (1)H-MRS Study. Sci Rep (2016) 0.76
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients (2015) 0.76
Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls. Transl Psychiatry (2015) 0.76
Characterization of Biosensors Based on Recombinant Glutamate Oxidase: Comparison of Crosslinking Agents in Terms of Enzyme Loading and Efficiency Parameters. Sensors (Basel) (2016) 0.75
Familial Influences on Mismatch Negativity and Its Association with Plasma Glutamate Level: A Magnetoencephalographic Study in Twins. Mol Neuropsychiatry (2016) 0.75
Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia. Schizophr Bull (2015) 0.75
Corticolimbic hyper-response to emotion and glutamatergic function in people with high schizotypy: a multimodal fMRI-MRS study. Transl Psychiatry (2017) 0.75
Schizophrenia as a disorder of communication. Schizophr Res Treatment (2013) 0.75
The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. Curr Neuropharmacol (2016) 0.75
Reduced γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk. Neural Plast (2016) 0.75
Brain-Derived Neurotrophic Factor and Suicide in Schizophrenia: Critical Role of Neuroprotective Mechanisms as an Emerging Hypothesis. Indian J Psychol Med (2016) 0.75
Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia. A single-voxel study in three regions involved in a pathogenetic theory. Neuroradiol J (2013) 0.75
Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. Diagnostics (Basel) (2015) 0.75
Fully automated macromolecule suppressed single voxel glutamate spectroscopy (FAMOUS SVGS). J Transl Med (2016) 0.75
Neuroimaging Biomarkers for Psychosis. Curr Behav Neurosci Rep (2015) 0.75
Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective. Biol Psychiatry (2017) 0.75
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci (2015) 0.75
The Kraepelinian dichotomy viewed by neuroimaging. Schizophr Bull (2014) 0.75
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7Tesla. Schizophr Res (2016) 0.75
Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T. BJPsych Open (2017) 0.75
Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. Biol Psychiatry (2017) 0.75
Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia. Front Psychiatry (2017) 0.75
Increased glutamate/GABA+ ratio in a shared autistic and schizotypal trait phenotype termed Social Disorganisation. Neuroimage Clin (2017) 0.75
Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature. NPJ Schizophr (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods (2006) 8.42
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24
NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol (2001) 6.96
The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell (1996) 6.96
Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry (1995) 5.59
Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 5.30
The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain (1999) 5.13
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry (2000) 4.84
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (2000) 4.66
Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience. Neuron (2003) 3.69
Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron (2007) 3.67
NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol (2006) 3.61
Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem (2000) 2.98
Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature (1995) 2.91
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 2.20
The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem (2006) 2.18
In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med (2001) 2.12
Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry (2005) 2.08
Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry (2005) 1.84
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull (2008) 1.80
Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry (2003) 1.79
In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol (2002) 1.79
Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol (2007) 1.78
Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron (2008) 1.78
Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry (2002) 1.68
Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eur J Neurosci (2007) 1.63
Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry (2004) 1.60
Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res (2009) 1.60
Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology (2006) 1.58
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 1.58
Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry (2007) 1.58
Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci (1998) 1.56
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther (2008) 1.55
Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging (2005) 1.55
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry (2009) 1.49
NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J Neurosci (2008) 1.47
Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit. Learn Mem (2008) 1.46
Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res (2008) 1.43
Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav (2005) 1.43
1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry (2009) 1.40
The way in which intervention studies have "personality" and why it is important to meta-analysis. Eval Health Prof (2001) 1.36
Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2010) 1.33
The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull (2008) 1.30
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry (2007) 1.29
Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1997) 1.28
3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry (2004) 1.27
Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry (2008) 1.27
Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia. Arch Gen Psychiatry (2008) 1.25
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res (2006) 1.22
Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology (2009) 1.20
Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust N Z J Psychiatry (2003) 1.14
Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry (2008) 1.13
Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry (2007) 1.12
Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res (2009) 1.12
Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res (2008) 1.11
Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry (2010) 1.10
Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2007) 1.09
Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed (2009) 1.08
Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res (2005) 1.04
Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res (2009) 1.04
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord (2009) 1.01
Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage (2009) 1.00
A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry (1999) 0.98
How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int (2006) 0.98
Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport (2001) 0.98
Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol (2008) 0.97
Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophr Res (2009) 0.97
An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull (1996) 0.96
Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res (2007) 0.96
Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit (2009) 0.95
Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci Biobehav Rev (2009) 0.94
Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res (2007) 0.92
1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol (1994) 0.92
A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. Schizophr Res (2008) 0.88
Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition. Psychopharmacology (Berl) (2004) 0.85
Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla. Br J Psychiatry (2002) 0.84
Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning. J Neurochem (2006) 0.81
Longitudinal 4.0 Tesla (31)P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatry Res (2009) 0.78
Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory. Neurosci Res (2003) 0.77
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur Neuropsychopharmacol (2010) 5.18
Efficiency of functional brain networks and intellectual performance. J Neurosci (2009) 4.25
Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain. Hum Brain Mapp (2009) 4.22
The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry (2006) 3.86
Aberrant frontal and temporal complex network structure in schizophrenia: a graph theoretical analysis. J Neurosci (2010) 3.80
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One (2009) 3.41
Genetic influences on human brain structure: a review of brain imaging studies in twins. Hum Brain Mapp (2007) 3.15
Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol (2012) 3.05
Affective state and decision-making in the Ultimatum Game. Exp Brain Res (2006) 2.91
Do women really have more bilateral language representation than men? A meta-analysis of functional imaging studies. Brain (2004) 2.86
Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry (2007) 2.70
Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res (2004) 2.61
Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp (2009) 2.55
Cannabis use and age at onset of schizophrenia. Am J Psychiatry (2004) 2.49
Abnormal rich club organization and functional brain dynamics in schizophrenia. JAMA Psychiatry (2013) 2.47
High-cost, high-capacity backbone for global brain communication. Proc Natl Acad Sci U S A (2012) 2.42
Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry (2003) 2.41
Auditory verbal hallucinations predominantly activate the right inferior frontal area. Brain (2008) 2.35
Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry (2008) 2.28
The association between brain volume and intelligence is of genetic origin. Nat Neurosci (2002) 2.21
Lateralization of amygdala activation: a systematic review of functional neuroimaging studies. Brain Res Brain Res Rev (2004) 2.05
Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol (2008) 2.05
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology (2007) 1.98
Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull (2012) 1.97
Genetic contributions to human brain morphology and intelligence. J Neurosci (2006) 1.97
Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry (2007) 1.95
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 1.90
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology (2008) 1.88
Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry (2011) 1.83
What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull (2008) 1.80
Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: a pilot project of the ENIGMA-DTI working group. Neuroimage (2013) 1.78
Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med (2008) 1.76
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. BMC Genomics (2012) 1.70
Reduced proactive inhibition in schizophrenia is related to corticostriatal dysfunction and poor working memory. Biol Psychiatry (2011) 1.70
Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol (2005) 1.69
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry (2002) 1.68
Diagnostic stability in a Dutch psychosis incidence cohort. Br J Psychiatry (2004) 1.67
Rich club organization of macaque cerebral cortex and its role in network communication. PLoS One (2012) 1.66
Impaired recognition and expression of emotional prosody in schizophrenia: review and meta-analysis. Schizophr Res (2007) 1.60
Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry (2007) 1.58
Deactivation of the parahippocampal gyrus preceding auditory hallucinations in schizophrenia. Am J Psychiatry (2010) 1.55
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Magnetic resonance imaging of boys with attention-deficit/hyperactivity disorder and their unaffected siblings. J Am Acad Child Adolesc Psychiatry (2004) 1.53
Repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex affects strategic decision-making. Neuroreport (2005) 1.52
Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry (2012) 1.51
Function of striatum beyond inhibition and execution of motor responses. Hum Brain Mapp (2005) 1.51
Sex steroids and brain structure in pubertal boys and girls. Psychoneuroendocrinology (2008) 1.50
Resting-brain functional connectivity predicted by analytic measures of network communication. Proc Natl Acad Sci U S A (2013) 1.50
Towards 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses. MAGMA (2008) 1.49
The same or different? A phenomenological comparison of auditory verbal hallucinations in healthy and psychotic individuals. J Clin Psychiatry (2011) 1.49
In vivo detection of cerebral cortical microinfarcts with high-resolution 7T MRI. J Cereb Blood Flow Metab (2012) 1.49
Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp (2011) 1.48
No evidence of microbleeds in ALS patients at 7 Tesla MRI. Amyotroph Lateral Scler (2010) 1.46
A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. PLoS One (2012) 1.45
Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging (2008) 1.44
Intracranial vessel wall imaging at 7.0-T MRI. Stroke (2011) 1.44
Heritability of regional and global brain structure at the onset of puberty: a magnetic resonance imaging study in 9-year-old twin pairs. Hum Brain Mapp (2009) 1.43
Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One (2013) 1.42
Social behavior and autism traits in a sex chromosomal disorder: Klinefelter (47XXY) syndrome. J Autism Dev Disord (2008) 1.39
Auditory hallucinations elicit similar brain activation in psychotic and nonpsychotic individuals. Schizophr Bull (2011) 1.39
Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biol Psychiatry (2010) 1.34
Genetic correlations between brain volumes and the WAIS-III dimensions of verbal comprehension, working memory, perceptual organization, and processing speed. Twin Res (2003) 1.31
Reliability of brain volumes from multicenter MRI acquisition: a calibration study. Hum Brain Mapp (2004) 1.31
Cardiorespiratory effects on default-mode network activity as measured with fMRI. Hum Brain Mapp (2009) 1.30
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol (2004) 1.30
Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study. PLoS One (2010) 1.30
Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2009) 1.30
The parcellation-based connectome: limitations and extensions. Neuroimage (2013) 1.29
Expectations and violations: delineating the neural network of proactive inhibitory control. Hum Brain Mapp (2012) 1.28
Diffusion-weighted MR neurography of the brachial plexus: feasibility study. Radiology (2008) 1.27
Increased gray-matter volume in medication-naive high-functioning children with autism spectrum disorder. Psychol Med (2005) 1.27
Clinical applications of 7 T MRI in the brain. Eur J Radiol (2011) 1.27
Volume changes in gray matter in patients with schizophrenia. Am J Psychiatry (2002) 1.27
Functional diffusion tensor imaging: measuring task-related fractional anisotropy changes in the human brain along white matter tracts. PLoS One (2008) 1.26